Commitment to ESG Principles

How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing?

Pharma's Almanac

Process Chemistry

Enabling Client Success with Complementary Services Built upon a Strong Chemistry Foundation

Jean-Francois Vincent-Rocan, Ph.D.

BIOVECTRA

International Markets

In what international markets do you anticipate significant developments in the near future?

Pharma's Almanac

Disruptive Technology

What do you view as the most disruptive or transformational technology or development on the horizon?

Pharma's Almanac

mRNA

Leveraging Existing Technologies with New Dedicated Facilities for mRNA Projects

Scott Doncaster; Marc Sauer, Ph.D.

BIOVECTRA

CDMO

Looking to Another 50 Years of Growth

Heather Delage; Oliver Technow

BIOVECTRA

Single-Use Technology

Facilitating Clinical Manufacturing of Recombinant Proteins with Large-Scale Single-Use Fermentation Technology

Scott Doncaster; Cameron Graham; Neil Morrison

BIOVECTRA

Branding

BioVectra's Strategic Brand Update

Oliver Technow

BIOVECTRA

Strategic Growth

Planning for Growth as Blockbusters Give Way to Personalized Medicine

BIOVECTRA

Partnership

BioVectra and PhaseBio Discuss Creating an Optimal Partnership

Oliver Technow; David Alvaro, Ph.D.; Jonathan Mow

BIOVECTRA

Meeting Two Trip Sponsors in Bratislava

Nigel Walker

Nice Insight

Complex Manufacturing

Enabling Commercial Manufacturing for Highly Complex Small Molecule Drugs Through Process Engineering and Technological Innovation

Scott Doncaster; Clarke MacDonald

BIOVECTRA

Recruitment

Living in Canada’s Coastal Paradise

BIOVECTRA

Expansion

Announcing Expansion for Enhanced Capabilities

Heather Delage

BIOVECTRA

Company Overview

Come Home to BioVectra

BIOVECTRA

Small Molecule API

Supporting Client Projects for CDMO Success

Marc Sauer, Ph.D.; Mark Wellman

BIOVECTRA